MHTP Technology Platform Review and change to services for 2019

MHTP Technology Platforms are an integral component of the MHTP research strategy, providing cutting edge capabilities and expertise to support research within the Precinct. Each Platform recently underwent a review to ensure alignment with current research resulting in several rationalisation strategies and actions have now been endorsed by executive management.

The following changes to services will take effect in early 2019:

1. Sanger Sequencing, Fragment Analysis, Microarray and Cell Line ID services will cease on March 31st 2019.

This primarily stems from Life Technologies and Agilent's decision to no longer support the ageing model of instruments (our 3130xl will be 14 years old and Scanner, 16 years old).

In early January, there will be a detailed change process communicated to all researchers for alternative options for these services.

Discussion are presently underway with Monash University's Micromon.

2. Quantstudio 6 (low throughput qPCR) services will be merged with the BioMark (high throughput qPCR) service by March 31st 2019.

The BioMark instrument will operate under a 'Do-It-Yourself' access mode following training and induction (i.e in line with use of the current Quantstudio 6 systems).

3. Diagnostic Mass Spectrometry capabilities will be relocated to Monash Pathology by March 31st 2019.

Remembering, Hudson Institute has a subscription to access instruments in Bio21 and support through the Monash Biomedical Proteomics Facility is also available.

Please do not hesitate to contact Vivien Vasic (Vivien.Vasic@hudson.org.au) should you require any further information prior to the change process communications in early January.

Thank you for your continuous support of the MHTP Technology Platforms and look forward to advancing capabilities to support your research in the new year.